Imagine having a master key that can unlock many different doors; this project is building a 'master key' medicine that works against several different families of dangerous viruses. Instead of waiting for a new virus to appear and then starting from scratch, they are finding molecules that already work against a wide range of threats. It's like having a fire extinguisher ready for any type of fire before the spark even happens.
Current antiviral treatments are too specific, meaning new medicines must be developed from scratch during every new pandemic. This delay increases mortality and overwhelms healthcare systems.
A high-throughput screening platform and a library of 300,000 molecules, alongside validated ex vivo lung models and nano-conjugation delivery systems.
If you are a drug discovery firm dealing with the high risk of single-target drug failure — this project developed a library of over 300,000 molecules that provides a diversified starting point for broad-spectrum antivirals. This reduces the time needed to find hits against multiple viral families.
If you are a research lab dealing with the difficulty of testing dangerous pathogens — this project developed human precision-cut lung slices and BSL-4 validation protocols. This allows for safer and more accurate testing of 17 confirmed compounds against Ebola virus.
If you are a developer dealing with poor drug delivery efficiency — this project developed innovative delivery systems using nano conjugation. This improves how antivirals reach their target in the body during a public health crisis.
Based on available project data, there is no information regarding the pricing or cost of the resulting antiviral candidates.
The project focuses on discovery, preclinical validation, and early clinical evaluation. Based on available project data, industrial scale-up details are not yet specified.
Based on available project data, the specific IP and licensing terms for the identified molecules are not provided.
The project runs from 2024-01-01 to 2028-12-31, with a roadmap including an adaptive platform trial for early clinical evaluation of 3 antivirals.
The project aims to facilitate long-term implementation of broad-spectrum antivirals in public health preparedness to reduce the burden on healthcare systems.
The consortium is a diverse 12-partner group across 9 countries, blending high-level research with commercial interests. With a 17% industry ratio (including 2 industry partners and 1 SME), the project maintains a strong academic and research core (9 partners) while ensuring a path toward commercialization and clinical application.
Contact the European Research Infrastructure on Highly Pathogenic Agents in Belgium
Contact us to explore licensing opportunities for the 160+ identified antiviral hits.
